First dose completed in phase 1 cannabinoid study
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile
Read More
Tag: cannabinoid
Cannabinoid company expands into oncology
OCTP develops cannabinoid medicines and is looking at potential treatment of cancer malignancies
Read More
UK Home Office loosens restrictions on GW’s Epidyolex
The cannabinoid has been reclassified as a Schedule 5 medicine meaning that it can be dispensed more easily
Read More
NHS fast-tracks access to Epidyolex for severe epilepsy
Doctors will be able to prescribe the drug from January 6
Read More
FDA approves GW’s cannabinoid drug Epidiolex
GW Pharmaceuticals’ Epidiolex has become the first cannabinoid prescription medicine to be approved in the US, winning clearance to treat two rare forms of epilepsy.
Read More
NEJM publishes second successful Epidiolex trial in LGS
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
Read More
FDA advisors back approval of GW’s Epidiolex
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Read More
GW’s cannabinoid fails in focal seizures trial
A mid-stage trial assessing an experimental cannabinoid being developed by GW Pharma for adults with focal seizures has failed to hit key targets.
Read More
Orphan status for GW’s rare epilepsy drug
London, UK-based GW Pharmaceuticals’ cannabinoid Epidiolex has been awarded Orphan status by European regulators as a treatment for Lennox-Gastaut Syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
Read More
GW planing to test its cannabinoids in cancer
GW Pharma is strengthening its focus on oncology after promising mid-stage data for its cannabis-based therapy in patients with a rare and aggressive brain tumour called glioblastoma multiforme (GBM).
Read More
GW Pharma’s cannabinoid hits targets in epilepsy trial
GW Pharmaceuticals has unveiled yet more positive data from a late-stage programme testing its cannabinoid Epidiolex in rare epilepsies, pushing its stock up more than 16 percent.
Read More
GW Pharma’s Epidiolex hits targets in rare epilepsy trial
GW Pharmaceuticals’ cannabinoid Epidiolex continues to impress in late-stage clinical trials, with a Phase III study involving patients with Lennox-Gastaut syndrome – a rare and severe form of childhood-onset epilepsy – the latest to hit its targets.
Read More
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
- Axol Bioscience acquires Newcells Biotech ophthalmology unit
- Nuclera and leadXpro partner to accelerate structure‑based drug design
